The Latin America, Middle East and Africa Lymphoma Therapeutics Market would witness market growth of 11.4% CAGR during the forecast period (2023-2029).
Targeted therapies are gaining attention as a potential treatment for lymphoma. Researchers' enhanced understanding of lymphoma cells has facilitated the development of novel drugs that specifically target distinct components of these cells. Targeted drugs are distinct from conventional chemotherapy drugs as they specifically target certain cells rather than attacking rapidly dividing cells. These pharmaceuticals are currently utilized for certain forms of NHL.
Currently, there is significant progress being made by scientists in comprehending the alterations in DNA within normal lymphocytes that may lead to the formation of lymphoma cells. Therefore, stem cell transplant is a technique that can be utilized in business. In addition, certain monoclonal antibodies recently created for lymphoma treatment could aid in eliminating residual cells.
Furthermore, researchers are currently investigating the efficacy of non-myeloablative stem cell transplants with reduced intensity for individuals diagnosed with lymphoma. CAR T-cell therapy is a viable technique for consideration. This procedure involves extracting T-cells from the patient's blood and modifying them in the laboratory to express chimeric antigen receptors (CARs) on their surface as part of the treatment. The receptors can bind with proteins on the lymphoma cells' surface and initiate a targeted immune response to eliminate them. Thus, such advancements in lymphoma therapeutics are expected to aid the market growth during the projected period.
In 2019, the third-leading cause of death in the UAE was identified as accounting for 10% of all mortality, following cardiovascular disease and injuries. The UAE has set a goal to decrease cancer mortality by approximately 18% by 2025. The UAE's national agenda includes reducing cancer-related deaths as a key performance indicator, in line with its commitment to providing world-class healthcare. Hence, with obesity, the chances of lymphoma prevalence in the general public are expected to increase, and the commitment of the government to decrease and effectively treat cancer cases is anticipated to give rise to the demand and availability for lymphoma therapeutics, aiding the market growth in the region.
The Brazil market dominated the LAMEA Lymphoma Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $449.9 million by 2029. The Argentina market is exhibiting a CAGR of 12% during (2023 - 2029). Additionally, The UAE market would showcase a CAGR of 11.1% during (2023 - 2029).
Based on Treatment Type, the market is segmented into Immune Therapy, Target Therapy, Chemotherapy, and Radiation Therapy. Based on Disease Type, the market is segmented into Non-Hodgkin Lymphoma, and Hodgkin Lymphoma. Based on Route of Administration, the market is segmented into Injectable, and Oral Route. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Lymphoma Therapeutics Market is Projected to reach USD 24.9 Billion by 2029, at a CAGR of 7.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Gilead Sciences, Inc., Seagen, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc. and Eli Lilly And Company.
By Treatment Type
By Disease Type
By Route of Administration
By Distribution Channel
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 